Top

Journal of Nephrology

Published in:

Open Access 01-04-2019 | Original Article

Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease

Authors: Ying Gao, Guiyun Wang, Yang Li, Chenxiao Lv, Zunsong Wang

Published in: Journal of Nephrology | Issue 2/2019

Abstract

Background

The relationship between oral activated charcoal (OAC) and hyperphosphatemia and vascular calcification is not completely clear. We observed and recorded the effects of OAC on hyperphosphatemia and vascular calcification in stage 3–4 chronic kidney disease (CKD).

Methods

In a randomized controlled study, we included 97 patients with stage 3–4 CKD. In the first phase of the experiment, the patients were randomly divided into the OAC group and placebo group. The endpoint of this phase was the development of hyperphosphatemia. The patients with hyperphosphatemia were selected into the second phase of the study. These patients underwent coronary artery multidetector computed tomography (MDCT) and were randomly divided into three groups: the OAC group, the calcium carbonate (CC) group and the lanthanum carbonate (LC) group.

Results

The first and second phases of the experiment were followed for 12 months. In the first phase of the experiment, there was a statistically significant difference in the proportion of patients with hyperphosphatemia between the OAC and placebo groups (28.57% vs. 79.17%, X² = 24.958, P = 0.000). In the second phase, the differences in coronary calcification score (CACS) between the OAC group, the CC group and the LC group were statistically significant (525.5 ± 104.2 vs 688.1 ± 183.7 vs 431.4 ± 122.5, P < 0.01).

Conclusion

Oral activated charcoal effectively delays the onset of hyperphosphatemia in patients with chronic kidney disease. OAC appears to delay the development of vascular calcifications in stage 3–4 CKD patients.

Available only for authorised users

Mizobuchi M, Towler D, Slatopolsky E (2009) Vascular calcification: the killer of patients with chronic kidney disease. J Am Soc Nephrol 20(7):1453–1464CrossRefPubMed

Blacher J, Guerin AP, Pannier B et al (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38(4):938–942CrossRefPubMed

Kumar V, Yadav AK, Singhal M et al (2018) Vascular function and cholecalciferol supplementation in CKD: a self-controlled case series. J Steroid Biochem Mol Biol. https://doi.org/10.1016/j.jsbmb.2018.01.001 CrossRefPubMed

Groothoff JW, Gruppen MP, Offringa M et al (2002) Mortality and causes of death of end stage renal disease in children: a Dutch cohort study. Kidney Int 61(2):621–629CrossRefPubMed

Chen NX, Moe SM (2012) Vascular calcification: pathophysiology and risk factors. Curr Hypertens Rep 14(3):228–237CrossRefPubMedPubMedCentral

Hill KM, Martin BR, Wastney ME et al (2013) Oral calcium carbonate affects calcium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 83(5):959–966CrossRefPubMed

Yamamoto et al (2017) Uremic toxicity and bone. CKD J Nephrol 30(5):623–627. https://doi.org/10.1007/s40620-017-0406-x (Epub 2017 Jun 1) CrossRefPubMed

Peeters MJ et al (2017) Abdominal aortic calcification in patients with CKD. J Nephrol 30(1):109–118. https://doi.org/10.1007/s40620-015-0260-7 (Epub 2016 Mar 22) CrossRefPubMed

Liu L, Liu Y, Zhang Y et al (2017) High phosphate-induced downregulation of PPARγ contributes to CKD-associated vascular calcification. J Mol Cell Cardiol 114:264–275. https://doi.org/10.1016/j.yjmcc.2017.11.021 CrossRefPubMed

10.

William KB, Paul TW (2010) Activated carbons prepared from refuse derived fuel and their gold adsorption characteristics. Environ Technol 31:125–137CrossRef

11.

Musso CG, Michelangelo H, Reynaldi J et al (2010) Combination of oral activated charcoal plus low protein diet as a new alternative for handling in the old end-stage renal disease patients. Saudi J Kidney Dis Transplant 21(1):102–104

12.

Floege J (2016) Phosphate binders in chronic kidney disease: a systematic review of recent data. J Nephrol 29(3):329–340. https://doi.org/10.1007/s40620-016-0266-9 CrossRefPubMed

13.

Behets GJ, Dams G, Damment SJ et al (2014) Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders. Am J Physiol Ren Physiol 306(1):61–67CrossRef

14.

Toussaint ND, Lau KK, Polkinghome KR et al (2011) Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology 16(3):290CrossRefPubMed

15.

Losito A, Nunzi E, Pittavini L et al (2018) Cardiovascular morbidity and long term mortality associated with in hospital small increases of serum creatinine. J Nephrol 31:71–77CrossRefPubMed

16.

Palmer SC, Hayen A, Macaskill P et al (2011) Serum levels of phosphorus, parathyroid hormone and calcium and risk of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305(11):1119–1127CrossRefPubMed

17.

Nicholas W, Chavkin J, Chia J et al (2015) Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res 333(1):39–48CrossRef

18.

Giachelli CM (2009) The emerging role of phosphate in vascular calcification. Kidney Int 75(9):890–897CrossRefPubMedPubMedCentral

19.

Al-Huseini I, Ashida N (2018) Deletion of IκB-kinase β in smooth muscle cells induces vascular calcification through β-catenin-runt-related transcription factor 2 signaling. J Am Heart Assoc. https://doi.org/10.1161/JAHA.117.007405 CrossRefPubMedPubMedCentral

20.

Chistiakov DA, Myasoedova VA, Melnichenko AA et al (2017) Calcifying matrix vesicles and atherosclerosis. BioMed Res Int 2017:7463590. https://doi.org/10.1155/2017/7463590 CrossRefPubMedPubMedCentral

21.

Gross P, Six I, Kamel S et al (2014) Vascular toxicity of phosphate in chronic kidney disease. Circ J 78(10):2339–2346CrossRefPubMed

22.

Lau WL, Festing MH, Giachelli CM (2010) Phosphate and vascular calcification: emerging role of the sodium-dependent phosphate co-transporter PiT-1. Thromb Haemost 104(3):464–470CrossRefPubMedPubMedCentral

23.

Zhang D, Bi X, Liu Y et al (2017) High phosphate-induced calcification of vascular smooth muscle cells is associated with the TLR4/NF-κb signaling pathway. Kidney Blood Press Res 42(6):1205–1215. https://doi.org/10.1159/000485874 CrossRefPubMed

Title: Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3–4 chronic kidney disease
Authors: Ying Gao
Guiyun Wang
Yang Li
Chenxiao Lv
Zunsong Wang
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Journal of Nephrology / Issue 2/2019
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI: https://doi.org/10.1007/s40620-018-00571-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2019

Effects of late cyclosporine withdrawal on renal graft function and survival

Glomerular isolated microscopic hematuria: urinary features and long term follow-up of a selected cohort of patients

Sodium removal by peritoneal dialysis: a systematic review and meta-analysis

Fibroblast growth factor-23 correlates with advanced disease conditions and predicts high risk of major adverse cardiac and cerebral events in end-stage renal disease patients undergoing continuous ambulatory peritoneal dialysis

Pediatric nephrolithiasis: a systematic approach from diagnosis to treatment

Myeloma light chain cast nephropathy, a review

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials